Iveta Dzivite
Glucocorticoids (GC) are essential medications widely used to treat various inflammatory diseases, with a considerable amount of the population receiving long-term GC therapy. However, prolonged use of GC often leads to glucocorticoid-induced osteoporosis (GIOP), a condition characterized by weakened bones and an increased risk of fractures, which carry significant morbidity and mortality. Our research focuses on exploring whether reinstating a natural daily trough in GC signaling can preserve bone quality while undergoing GC treatment, without compromising the anti-inflammatory effects of the medication. Additionally, we aim to study the pathophysiology of GIOP and unravel in more detail how the cell types in bone are targeted by the GC treatment and our interventions.
